BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, January 18, 2025
See today's BioWorld Asia
Home
» After Zika cure, Tychan accelerates monoclonal antibody for yellow fever
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
After Zika cure, Tychan accelerates monoclonal antibody for yellow fever
Dec. 12, 2018
By
David Ho
No Comments
HONG KONG – In just seven months, Singapore-based biotech company Tychan Pte Ltd. has moved its monoclonal antibody, TY-014, from initiation and into clinical development.
BioWorld Asia
